Taysha Gene Therapies' R&D Chief Sells $1.2 Million in Stock
Nagendran Sukumar, president and head of R&D at Taysha Gene Therapies (NASDAQ: TSHA), sold 200,000 shares for $1.2 million on July 10, 2026 under a Rule 10b5-1 trading plan. The stock has seen a one-year total return of 149%, closing at $6.57 as of July 9, 2026.
Tickers: $TSHA
Topics: Rule 10b5-1 plan SEC filing stock sale